Cargando…

Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series

OBJECTIVE: Combination biological therapies are being considered increasingly for patients with multiple co-morbidities requiring biologics. There are limited data available on this approach, and concerns remain about the possible risk of adverse events, particularly infection. METHODS: We present t...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Mariam, Jones, Bryony, Williams, Emma, Kurukulaaratchy, Ramesh, Holroyd, Chris, Mason, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923700/
https://www.ncbi.nlm.nih.gov/pubmed/36789243
http://dx.doi.org/10.1093/rap/rkad018
_version_ 1784887771527118848
author Malik, Mariam
Jones, Bryony
Williams, Emma
Kurukulaaratchy, Ramesh
Holroyd, Chris
Mason, Alice
author_facet Malik, Mariam
Jones, Bryony
Williams, Emma
Kurukulaaratchy, Ramesh
Holroyd, Chris
Mason, Alice
author_sort Malik, Mariam
collection PubMed
description OBJECTIVE: Combination biological therapies are being considered increasingly for patients with multiple co-morbidities requiring biologics. There are limited data available on this approach, and concerns remain about the possible risk of adverse events, particularly infection. METHODS: We present three patients on dual biologics for rheumatic disease and asthma. The biologic combinations used were etanercept and mepolizumab, infliximab and omalizumab, and etanercept and omalizumab. The time on combination biologic therapies ranged from 24 to 36 months. Patients were monitored for any serious adverse events. RESULTS: All three patients were able to tolerate combined biologic therapies, with no serious adverse events. All three patients gained improvement in their rheumatic and asthma disease control, with reduction in disease activity scores and reduction in steroid usage. CONCLUSION: The decision to start dual biologic therapy should be considered carefully, on a case-by-case basis. The number of patients who are on combination biological therapy is small, and data are sparse. Real-world data are needed to examine the long-term benefits and risks of different forms of combination biologic therapies.
format Online
Article
Text
id pubmed-9923700
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-99237002023-02-13 Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series Malik, Mariam Jones, Bryony Williams, Emma Kurukulaaratchy, Ramesh Holroyd, Chris Mason, Alice Rheumatol Adv Pract Concise Report OBJECTIVE: Combination biological therapies are being considered increasingly for patients with multiple co-morbidities requiring biologics. There are limited data available on this approach, and concerns remain about the possible risk of adverse events, particularly infection. METHODS: We present three patients on dual biologics for rheumatic disease and asthma. The biologic combinations used were etanercept and mepolizumab, infliximab and omalizumab, and etanercept and omalizumab. The time on combination biologic therapies ranged from 24 to 36 months. Patients were monitored for any serious adverse events. RESULTS: All three patients were able to tolerate combined biologic therapies, with no serious adverse events. All three patients gained improvement in their rheumatic and asthma disease control, with reduction in disease activity scores and reduction in steroid usage. CONCLUSION: The decision to start dual biologic therapy should be considered carefully, on a case-by-case basis. The number of patients who are on combination biological therapy is small, and data are sparse. Real-world data are needed to examine the long-term benefits and risks of different forms of combination biologic therapies. Oxford University Press 2023-02-03 /pmc/articles/PMC9923700/ /pubmed/36789243 http://dx.doi.org/10.1093/rap/rkad018 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Concise Report
Malik, Mariam
Jones, Bryony
Williams, Emma
Kurukulaaratchy, Ramesh
Holroyd, Chris
Mason, Alice
Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
title Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
title_full Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
title_fullStr Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
title_full_unstemmed Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
title_short Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
title_sort dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
topic Concise Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923700/
https://www.ncbi.nlm.nih.gov/pubmed/36789243
http://dx.doi.org/10.1093/rap/rkad018
work_keys_str_mv AT malikmariam dualbiologictherapyforthetreatmentofrheumaticdiseasesandasthmaacaseseries
AT jonesbryony dualbiologictherapyforthetreatmentofrheumaticdiseasesandasthmaacaseseries
AT williamsemma dualbiologictherapyforthetreatmentofrheumaticdiseasesandasthmaacaseseries
AT kurukulaaratchyramesh dualbiologictherapyforthetreatmentofrheumaticdiseasesandasthmaacaseseries
AT holroydchris dualbiologictherapyforthetreatmentofrheumaticdiseasesandasthmaacaseseries
AT masonalice dualbiologictherapyforthetreatmentofrheumaticdiseasesandasthmaacaseseries